drugset / Trial / NCT06208748
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Phase 2
Active not recruiting
40 enrolled
Sarcoma Alliance for Research through Collaboration
Cogent Biosciences, Inc. · collabDana-Farber Cancer Institute · collabThe Life Raft Group · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bezuclastinib | Small molecule | 600 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |